

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/780,114
		Filing Date	February 9, 2001
		First Named Inventor	Nobori, Tsutomu
		Group Art Unit	4655 1634
		Examiner Name	Not yet assigned
Sheet 1 of 3	Attorney Docket Number		023070-103031US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
88	A1	US 4,683,195		Mullis, et al.	07-28-1987	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner Signature	<i>J. Goldberg</i>	Date Considered	8/9/02
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1339363 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete if Known

Application Number	09/780,114
Filing Date	February 9, 2001
First Named Inventor	Nobori, Tsutomu
Group Art Unit	1655
Examiner Name	Not yet assigned
Attorney Docket Number	02307O-103031US



## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>gy</i>	C1	Abeles, et al. "A Methionine Salvage Pathway" <i>Aldrichimica Acta</i> (1992) Vol. 25(1), pp. 2-7.	
	C2	Fitchen, et al. "Methylthioadenosine Phosphorylase Deficiency in Human Leukemias and Solid Tumors" <i>Cancer Research</i> (October 1986) Vol. 46, pp. 5409-5412.	
	C3	Kamatani and Carson, "Dependence of Adenine Production Upon Polyamine Synthesis in Cultured Human Lymphoblasts" <i>Biochimica et Biophysica Acta</i> (1981) Vol. 675, pp. 344-350.	
	C4	Kamantani, et al. "Selective Killing of Human Malignant Cell Lines Deficient in Methylthioadenosine Phosphorylase, A Purine Metabolic Enzyme" <i>Proc. Natl. Acad. Sci. USA</i> (February 1981) Vol. 78(2), pp. 1219-1223.	
	C5	Kohler, et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <i>Nature</i> (1975) Vol. 256, pp. 495-497.	
	C6	Kohsaka, et al. "Microtiter Format Gene Qualification by Covalent Capture of Competitive PCR..." <i>Nucleic Acids Research</i> (1993) Vol. 21(15), pp. 3469-3472.	
	C7	Kohsaka and Carson, "Solid-phase Polymerase Chain Reaction" <i>The Sam &amp; Rose Stein Institute for Research on Ageing-UCSD Dept. of Medicine</i> (No Date) pp. 1-6 with 2 Figures.	
	C8	Kreis, et al. "Biological Effects of Enzymatic Deprivation of L-Methionine in Cell Culture and an Experimental Tumor" <i>Cancer Research</i> (August 1973) Vol. 33, pp. 1866-1869.	
	C9	Kreis, Willi "Tumor Therapy by Deprivation of L-Methionine: Rationale and Results" <i>Cancer Treatment Reports</i> (June 1979) Vol. 63(6), pp. 1069-1072.	
	C10	Kreis, et al. "Methionine Dependency of Malignant Tumors" <i>J. Nat. Cancer Inst.</i> (1991) Vol. 10(83), pp. 725.	
	C11	Lockwood, et al. "Purification and Characterization of Methionine γ-lyase from <i>Trichomonas vaginalis</i> " <i>Biochem. J.</i> (1991) Vol. 279, pp. 675-682.	
	C12	Muss, et al. "A Phase II Trial of peg-L-asparaginase in the Treatment of Non-hodgkins Lymphoma" <i>Investigational New Drugs</i> (1990) Vol. 8, pp. 125-130.	

Examiner  
Signature

*J. Goldberg*

Date  
Considered

*8/1/02*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1339363 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/780,114
Filing Date	February 9, 2001
First Named Inventor	Nobori, Tsutomu
Group Art Unit	1655
Examiner Name	Not yet assigned
Attorney Docket Number	023070-103031US

Sheet 3 of 3



## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Jey	C13	Nakayama, <i>et al.</i> "Specific Labeling of the Essential Cysteine Residue of L-Methionine $\gamma$ -lyase with a Cofactor Analogue, N-(Bromoacetyl)pyridoxamine Phosphate" <i>Biochemistry</i> (1988) Vol. 27, pp. 1587-1591.	
	C14	Nobori, <i>et al.</i> "Absence of Methylthioadenosine Phosphorylase in Human Gliomas" <i>Cancer Research</i> (June 1991) Vol. 51, pp. 3193-3197.	
	C15	Nobori, <i>et al.</i> "Methylthioadenosine Phosphorylase Deficiency in Human Non-small Cell Lung Cancers" <i>Cancer Research</i> (March 1993) Vol. 53, pp. 1098-1101.	
	C16	Nobori, <i>et al.</i> "Deletions of the Cyclin-dependent Kinase-4 Inhibitor Gene in Multiple Human Cancers" <i>Nature</i> (April 1994) Vol. 368, pp. 753-756.	
	C17	Nosoh, <i>et al.</i> "Protein Stabilization and Stability Through Protein Engineering" <i>Ellis Horwood, N.Y.</i> (1991) Vol. 143, pp. 62	
	C18	Ragione, <i>et al.</i> "Physicochemical and Immunological Studies on Mammalian 5'-deoxy-5'-methylthioadenosine Phosphorylase" <i>J. of Biological Chemistry</i> (1990) Vol. 265(11), pp. 6241-6246.	
	C19	Ragione, <i>et al.</i> "Deficiency of 5'-deoxy-5'-methylthioadenosine Phosphorylase Activity in Malignancy" <i>Biochem J.</i> (1992) Vol. 281, pp. 533-538.	
	C20	Ragione, <i>et al.</i> "Enzyme Deficiency and Tumor Suppressor Genes: Absence of 5'-deoxy-5'-methylthioadenosine Phosphorylase in Human Tumors" <i>Adv. Exp. Med &amp; Biol.</i> (1993) Vol. 348, pp. 31-43.	
	C21	Ragione, <i>et al.</i> "5'-deoxy-5'-methylthioadenosine Phosphorylase and p16 <sup>INK4</sup> Deficiency in Multiple Tumor Cell Lines" <i>Oncogene</i> (1995) Vol. 10, pp. 827-833.	
	C22	Shibui, <i>et al.</i> "A New Hybrid Promoter and Its Expression Vector in <i>Escherichia coli</i> " <i>Agric. Biol. Chem</i> (1988) Vol. 52(4), pp. 983-988.	
C23	Zappia, <i>et al.</i> "Progress in Polyamine Research" published 1988 by Plenum Press (New York), pp. 179-238.		

MAY 08 2002

RECEIVED

Examiner  
Signature

J. Goldberg

Date  
Considered

8/9/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1339363 v1